Should you have adjuvant chemotherapy–treatment after pancreatic cancer surgery? Dr. Marco Del Chiaro explains that the evidence says “yes.”
Researchers are comparing effectiveness of chemotherapy before surgery (neoadjuvant) with chemotherapy after surgery (adjuvant).
Is chemotherapy before and after pancreatic cancer surgery more effective than just chemotherapy after surgery?
Dr. Jennifer Knox is leading the NeoPancONE trial for a biomarker that indicates which patients will respond better to certain chemotherapy before surgery.
When you start pancreatic cancer treatment it seems like everyone is speaking a language you don’t know. Here are 18 important words to help you along.
Harvey Parker had genetic testing as part of his initial pancreatic cancer treatment. The BRCA2 mutation led him to a PARP inhibitor clinical trial.
New clinical guidelines from the American Society for Radiation Oncology will help clarify the best uses of radiation treatment for pancreatic cancer.
Multicenter Trial Focuses on Neoadjuvant Treatment for Borderline Resectable and Locally Advanced Disease
Dr. David Ryan outlines a new trial for pre-surgical pancreatic cancer treatment combining a blood pressure drug, immunotherapy, standard care and SBRT.
A clinical trial compares two chemotherapy regimens to see which one is more effective at knocking out remaining cancer cells.
David Dessert explains that his aunt’s genetic testing for BRCA2 mutation directed his own treatment for pancreatic cancer.